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T he Age of Enlightenment in world history occurred several centuries ago and reflected a shift from theological authority toward reason and the scientific method. In health care, the evolution of evidence-based medicine as a basis for clinical decisions (as opposed to previously described eminence-, vehemence-, eloquence-, providence-, diffidence-, nervousness-, or confidence-based approaches 1 ) is a late 20th-century phenomenon that reached its zenith in the randomized controlled trial (RCT). In a hierarchy of methods of obtaining evidence, the RCT stood at the top. It evaluated the efficacy of a treatment while carefully controlling for the noise of variables other than the experimental intervention itself, which might account for findings. More recently, systematic reviews and meta-analyses have aggregated RCTs using strict standards for inclusion, such that not all RCTs make the cut; only the pristine RCTs contribute to the funnel plots and effect sizes that reflect a series of studies of a particular intervention for a specific disorder.
Disquiet and even skepticism among clinicians about the results of such RCTs emanates from multiple sources, ranging from the inclusion and (or) exclusion criteria to the source of the research funding to the enthusiasm of the investigators for the experimental intervention.
In seeking to apply experimental findings to their daily work, clinicians have looked at the profiles of research subjects in clinical trials to see if they resemble patients in their practice. Zimmerman et al 2 in Rhode Island systematically evaluated a series of over 300 uni-or bipolar depressed outpatients presenting for clinical care at the outpatient psychiatry clinic of a large general hospital. All patients received psychometric as well as clinical evaluation. They were then screened for the presence of exclusion criteria for RCTs of antidepressants (ADs) as described in a series of published studies of depression in major psychiatric journals. Whether owing to comorbidity (anxiety or personality disorder), symptom severity or duration, or suicidal ideation, up to 86% of the sample met exclusion criteria for published RCTs for depression. In other words, the findings from the RCTs on the efficacy of ADs may not reflect the real world of their use in clinic patients. This finding has been echoed recently by the finding that of the 2855 participants in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) effectiveness trial for depression, only 22.2% met entry criteria for typical Phase 3 efficacy trials of ADs. 3 Concerns and evidence in the scientific and public arenas about the role of the pharmaceutical industry in the sponsorship of clinical trials and the impact on study design, data interpretation, and dissemination of results has also engendered not only cynicism but also new standards for clinical trials registration, publication, and disclosure. It has also been associated with a reinvestment by peer-reviewed funding agencies in treatment research.
Finally, despite the proliferation of psychiatric diagnoses with each iteration of the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders, the varieties of recommended treatments seemed to be headed in the opposite direction; atypical antipsychotics have been studied in various clinical conditions apart from schizophrenia, and cognitive-behavioural therapy has appeared to be effective for a wide array of disorders, including psychoses. Scott 4 has provided a note of healthy skepticism on the "efficacy-effectiveness gap" p 401 for both pharmaco-and psychotherapy in this regard.
The rationale for and essential ingredients of effectiveness trials have been ably articulated by March et al. 5 The emphases include recruitment from real-life clinical practice settings of a heterogeneous and representative clinical sample in sufficient number to identify small to moderate differences, interventions that can be readily implemented in clinical practice, the use of simple and clinically relevant outcome measures, and randomization within the study design.
In the last decade, this logic has been translated into the 4 major trials for 3 major psychiatric disorders, described in this The return on this $100-million investment has been sobering; the previously touted superiority of atypical SGAs led to profound changes, both in prescribing behaviour and in cost. The major effectiveness trials described by Dr George Foussias and Dr Gary Remington 9 challenge the evidence for this shift. The separate ongoing study of issues of mortality in the context of antipsychotics continues to raise alarming questions and to provide new evidence for the benefits of clozapine. 10 Will we see a return to the use of FGAs in the context of this evidence? Will clozapine become more popular? Will new pharmacological agents emerge that reflect different paradigms of understanding and treatment of psychosis? Will new strategies for adherence bear fruit?
As for the depression effectiveness trial summarized by Dr Mark Sinyor, Dr Ayal Schaffer, and Dr Anthony Levitt, 11 how do we reconcile our depression-is-treatable message with the sobering remission rates that are lower than seen in RCTs? As for the equal outcomes in the first level of treatment by psychiatrists and family physicians, does this suggest that true specialist psychopharmacology by a psychiatrist for a person with depression should only follow a course of treatment administered by a family physician if unsuccessful? Dishearteningly, the evidence for reliable detection of depression in primary care remains suboptimal according to a recent meta-analysis. 12 Finally, the bipolar disorder effectiveness trial, STEP-BD, synthesized by Dr Sagar V Parikh, Dr Serge R LeBlanc, and Ms Melina M Ovanessian 13 sheds new light both on clinical course and on treatment response. It reminds us that bipolar depression is particularly disabling as well as poorly responsive to AD pharmacotherapy, leaving the clinician in a conundrum regarding management. How does the clinician withhold ADs from the depressed patient with bipolar depression? What are the practical alternatives? Where does electroconvulsive therapy fit in?
These effectiveness trials for the major psychiatric disorders we face should engender both humility about our treatments and a sense of urgency to develop and evaluate new ones; our patients deserve nothing less.
